Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

PHASE3CompletedINTERVENTIONAL
Enrollment

532

Participants

Timeline

Start Date

March 26, 2015

Primary Completion Date

March 27, 2023

Study Completion Date

March 27, 2023

Conditions
Acute Cerebral Ischemia
Interventions
DRUG

Nerinetide (NA-1)

DRUG

Placebo

Trial Locations (4)

V1Y 1T2

Kelowna General Hospital, Kelowna

V3L 3W7

Royal Columbian Hospital, New Westminster

V5M 4X6

British Columbia Ambulance Service and British Columbia Emergency Health Services, Vancouver

V5Z 1M9

Vancouver General Hospital, Vancouver Coastal Health, Vancouver

All Listed Sponsors
collaborator

Brain Canada

OTHER

collaborator

Djavad Mowafaghian Centre for Brain Health

UNKNOWN

collaborator

Canadian Stroke Network

OTHER

collaborator

University of Calgary

OTHER

collaborator

University of Toronto

OTHER

collaborator

University of British Columbia

OTHER

collaborator

Genome British Columbia

INDUSTRY

lead

NoNO Inc.

INDUSTRY

NCT02315443 - Field Randomization of Nerinetide (NA-1) Therapy in Early Responders | Biotech Hunter | Biotech Hunter